**Specifications Table**TableSubject area*Biomedicine*More specific subject area*Cardiology, Heart Failure*Type of data*Tables*How data was acquired*A visit in two specialized outpatient Heart Failure units as well as retrieval of historical records. The circulating biomarker levels were quantified from serum and plasma collected from the patients on the enrolment day.*Data format*Filtered, analyzed.*Experimental factors*Blood samples from the HF patients were collected on from an antecubital vein. To measure BNP levels, whole blood was collected in a chilled tube with the anticoagulant EDTA and was centrifuged at RCF 1800 g for 10 min at 4 °C. Serum samples for hs-TnT, Gal-3, CICP and sAXL analysis were kept at room temperature for at least 30 min after blood extraction and were later centrifuged at RCF 1800 g for 10 min at room temperature. The supernatants were collected, aliquoted and kept at −80 °C until analysis.*Experimental features*The ELISA assays used to quantify the circulating biomarkers' levels were:*--*the high sensitivity TnT assay (Troponin T high sensitive (05092744 119), Roche Diagnostics)*--*Galectin-3 Platinum ELISA (BMS279/2CE, eBioscience)*--*the MicroValue CICP ELISA assay (8003, Siemens Diagnostics).*--*a chemiluminometric immunoassay run on the ADVIA Centaur Immunochemistry analyzer for BNP (Siemens Diagnostics).*--*sAXL quantification was devised in our laboratory using commercially available antibodies.*Data source location*Hospital Clinic and Hospital Sant Pau, Barcelona, Spain.*Data accessibility*The available data is with this article*

**Value of the data**

•The data presented in this DIB article is important for interpretation of the circulating levels of the biomarkers that we describe in our study.

•Heart failure is the end-stage of many heart diseases and its development can be highly variable among patients.

•Many results from the literature are difficult to compare due to heterogeneity of the heart failure cohorts analyzed.

•The full description of the HF cohort patients and of the circulating biomarkers and their relationship with the clinical characteristics of the patients will provide deeper insight to the researchers that work in the same field and will allow more meaningful comparisons.

1. Data {#s0005}
=======

In this Data in Brief article, we provide the baseline demographic, prior history, ECG, echocardiographic, laboratory and pharmacological parameters of 192 patients with heart failure and reduced ejection fraction ([Table 1](#t0005){ref-type="table"}). The distribution of the circulating values of five biomarkers and their relationship with the patient´s clinical characteristics is also given [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}.

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Patient enrolment and collection of clinical data {#s0015}
------------------------------------------------------

A detailed description of subject enrollment and collection of clinical data has been reported previously [@bib1].

2.2. Data analysis {#s0020}
------------------

Descriptive values are given as mean and standard error of the mean (SEM), or as frequencies (%) or as quartile values. Correlation analysis among biomarkers and these with clinical laboratory values were performed with Pearson correlation coefficient. Statistical analysis was performed using the SPSS software. Statistical significance was indicated by *P* value \<0.05. A detailed description data analysis can be found elsewhere [@bib1], [@bib2].

Transparency document. Supplementary material {#s0030}
=============================================
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###### 

Clinical characteristics of HF patients.

Table 1

  Parameter                                 Mean±SEM or %   *n*
  ----------------------------------------- --------------- -----
  **[Demographics]{.ul}**                                   
  Age (years)                               62±1            192
  Male (%)                                  85              164
  Female (%)                                15              28
                                                            
  **[Risk factors]{.ul}**                                   
  Hypertension (%)                          76              143
  Dyslipidemia (%)                          62              115
  Diabetes mellitus (%)                     35              66
  Current/former smoker (%)                 70              132
  Previous AMI (%)                          48              90
                                                            
  **[Etiology]{.ul}**                                       
  Idiopathic (%)                            28              53
  Ischemic (%)                              48              93
  Valvular (%)                              12              23
  Hypertensive (%)                          2.6             5
  Other (%)                                 9.4             18
                                                            
  **[Clinical characteristics]{.ul}**                       
  NYHA FC II (%)                            72              138
  NYHA FC III-IV (%)                        28              54
  Body mass index (kg/m^2^)                 28.1±0.4        183
  Abdominal perimeter (cm)                  103.0±1.1       158
  Heart rate (beats/min)                    72±1            190
  Systolic blood pressure (mmHg)            117.2±1.6       184
  Diastolic blood pressure (mmHg)           72.0±0.9        183
  Pulse pressure (mmHg)                     45.5±1.4        183
  6-min walk distance (m)                   408.5±8.0       171
                                                            
  **[Symptoms and signs]{.ul}**                             
  Paroxysmal nocturnal dyspnea (%)          17              30
  Reduction exercise tolerance (%)          44              74
  Orthopnea (%)                             29              51
  Syncope (%)                               13              23
  Lower extremity edema (%)                 14              24
  Congestion signs (%)                      10              10
  Jugular venous distension (%)             12              12
  Hepatojugular reflux (%)                  19              18
                                                            
  **[ECG parameters]{.ul}**                                 
  Sinusal rhythm (%)                        59              110
  Atrial fibrillation (%)                   9               17
  Necrosis Q waves (%)                      32              39
  Intervent. Conduct. disorders (%)         63              105
  Left bundle branch block (%)              23              26
  Pacemaker (%)                             55              106
  Resynchronization therapy (%)             12              23
  QRS length (ms)                           134.7±2.8       180
  Interval PR (ms)                          168.9±3.4       123
                                                            
  **[Echocardiographic parameters]{.ul}**                   
  LVESD (mm)                                53.6±0.9        167
  LVEDD (mm)                                67.4±0.7        181
  LVEF (%)                                  27.3±0.5        192
  LAD (mm)                                  48.2±0.7        173
  IVST (mm)                                 10.4±0.1        180
  LVPWT (mm)                                10.0±0.1        174
  LVH (%)                                   45              81
                                                            
  **[Laboratory values]{.ul}**                              
  Serum creatinine (mg/dL)                  1.18±0.03       189
  GFR (mL/min)                              56.6±0.7        178
  Sodium (mEq/L)                            139.8±0.2       190
  Potassium (mEq/L)                         4.6±0.04        188
  Aspartate aminotransferase (UI/L)         26.1±1.4        182
  Alanine aminotransferase (U/L)            27.5±2.3        188
  Bilirubin (mg/dL)                         0.82±0.04       185
  Uric acid (mg/dL)                         6.98±0.17       132
  Glucose (mg/dL)                           115.0±2.6       189
  Total Cholesterol (mg/dL)                 169.4±2.8       172
  HDL Cholesterol (mg/dL)                   40.7±0.7        167
  LDL Cholesterol (mg/dL)                   103.3±2.3       167
  Triglycerides (mg/dL)                     128.7±4.8       180
  C Reactive Protein (mg/dL)                0.88±0.19       143
  Thyrotropin (mUI/L)                       3.1±0.6         171
  Thyroxine (ng/dL)                         1.31±0.02       150
  Hemoglobin (g/L)                          136.7±1.2       187
  Hematocrit (L/L)                          0.419±0.003     189
  Erythrocyte count (10E12/L)               4.57±0.04       183
  Lymphocytes count (10E9/L)                1.8±0.05        188
  Platelet count (10E9/L)                   218.2±4.6       184
                                                            
  **[Pharmacological treatment]{.ul}**                      
  ACEI (%)                                  68              125
  ARB(%)                                    24              43
  ACEI and/or ARB (%)                       90              168
  Beta-blocker (%)                          94              176
  Ca-antagonists (%)                        8               15
  Antithromb and/or anticoagul (%)          81              151
  Statins (%)                               62              116
  Antidiabetics (%)                         28              52
  Diuretics (%)                             79              146
  Antialdosteronic agents (%)               55              102
  Digoxin (%)                               11              21
  Antiarrhythmics (%)                       22              41
  Nitrates (%)                              13              25
  Hydralazine (%)                           4               8
  Anemia treatment (%)                      4               8

NYHA FC (New York Heart Assotiation functional class), AMI (acute myocardial infarction), Intervent conduct disorders (Interventricular conduction disorders), LVESD (left ventricle end-systolic diameter), LVEDD (left ventricle end-diastolic diameter), LVEF (left ventricle ejection fraction), LAD (Left atrial diameter), IVST (Interventricular septum thickness), LVPWT (Left ventricular posterior wall thickness), LVH (Left Ventricular Hypertrophy defined as IVST ≥11 mm),GFR (Glomerular filtration rate), ACEI (Angiotensin Converting Enzyme Inhibitor), ARB (Angiotensin Receptor Blocker), Antithromb and/or anticoagul (Antithrombotic and/or anticoagulant).

###### 

Quartile values of the serum biomarkers studied.

Table 2

  Quartile   Hs-TnT (pg/mL)   Gal-3 (ng/mL)   CICP (ng/mL)   sAXL (ng/mL)   BNP (pg/mL)
  ---------- ---------------- --------------- -------------- -------------- -------------
  1st        11.0             4.9             68.6           69.1           76.2
  2nd        17.4             5.8             85.6           82.4           167.7
  3rd        28.7             7.5             112.3          98.1           362.7

High sensitivity Troponin T (hs-TnT), galectin-3 (Gal-3), C-terminal propeptide of type I procollagen (CICP), soluble AXL (sAXL) and Brain Natriuretic Peptide (BNP).

###### 

Profiles of HF patients that have a serum biomarker value above the third quartile value.

Table 3

  Characteristic                 3Q_Hs-TnT   3Q_Gal-3   3Q_CICP    3Q_BNP
  ------------------------------ ----------- ---------- ---------- ----------
  *n*                            47          47         45         41
  Age (years)                    62±1        65±2       58±2       61±2
  Sex (%M / %F)                  89/11       79/21      80/20      88/12
  Hypertension (%)               77          85         58         66
  Diabetes mellitus (%)          38          47         27         27
  Dyslipidemia (%)               60          57         51         46
  Idiopathic etiology (%)        28          34         29         29
  Ischemic etiology (%)          51          47         47         46
  Valvular etiology (%)          13          11         11         12
  Hypertensive etiology (%)      0           2          4          2
  Other etiology (%)             8           6          9          10
  NYHA FC II (%)/ FCIII_IV (%)   57/43       57/43      56/44      51/49
  LVEF (%)                       24.2±1.1    26.1±1.1   25.7±1.1   21.4±1.0

High sensitivity Troponin T (hs-TnT), galectin-3 (Gal-3), C-terminal propeptide of type I procollagen (CICP), soluble AXL (sAXL) and Brain Natriuretic Peptide (BNP). New York Heart Association Funtional class II or III_IV (NYHA FC II FCIII_IV), left ventricular ejection fraction (LVEF).

###### 

Pearson correlation analysis of the HF_REF patients' biomarker levels.

Table 4

                            Number of pairs   *R* coefficient   *P* value
  ------------------------- ----------------- ----------------- -----------
  Ln(hs-TnT) vs Ln(Gal-3)   189               0.25              \<0.001
  Ln(hs-TnT) vs Ln(CICP)    179               0.12              NS
  Ln(hs-TnT) vs Ln(sAXL)    191               0.28              \<0.0001
  Ln(hs-TnT) vs Ln(BNP)     166               0.51              \<0.0001
  Ln(Gal-3) vs Ln(CICP)     178               0.044             NS
  Ln(Gal-3) vs Ln(sAXL)     190               0.27              \<0.001
  Ln(Gal-3) vs Ln(BNP)      166               0.27              \<0.001
  Ln(CICP) vs Ln(sAXL)      180               0.17              \<0.05
  Ln(CICP) vs Ln(BNP)       157               0.26              0.001

###### 

Pearson correlation analysis of the HF_REF patients' biomarker levels with patients' biochemical parameters.

Table 5

  Laboratory values         Ln(hs-TnT)   Ln(Gal-3)   Ln(CICP)                                         
  ------------------------- ------------ ----------- ---------- ----- ------- ---------- ----- ------ --------
  Serum creatinine(mg/dL)   188          0.43        \<0.0001   187   0.34    \<0.0001   177   0.15   \<0.05
  GFR (mL/min)              177          −0.41       \<0.0001   177   −0.34   \<0.0001                NS
  Sodium (mEq/L)            189          −0.24       \<0.001    188   −0.21   \<0.01                  NS
  Potassium (mEq/L)                                  NS                       NS                      NS
  AST (IU/L)                                         NS                       NS         170   0.18   \<0.05
  ALT (IU/L)                                         NS                       NS                      NS
  Total bilirubin (mg/dL)   184          0.22        \<0.01                   NS                      NS
  Glucose (mg/dL)                                    NS                       NS                      NS
  Uric acid (mg/dL)         131          0.39        \<0.0001   132   0.2     \<0.05                  NS

GFR (glomerular filtration rate), AST (aspartate transaminase), ALT (alanine transaminase).

###### 

Pearson correlation analyses of the Ln of the biomarkers levels with patients' blood count and inflammation parameters.

Table 6

  Laboratory values               Ln(hs-TnT)   Ln(Gal-3)   Ln(CICP)                    
  ------------------------------- ------------ ----------- ---------- -- -- ---- -- -- ----
  Leukocyte count (x10^9^/L)                               NS               NS         NS
  Platelet count (x10^9^ /L)      183          −0.22       \<0.01           NS         NS
  Neutrophils (x10^9^/L)          187          0.17        \<0.05           NS         NS
  Lymphocytes (x10^9^/L)          187          −0.26       \<0.001          NS         NS
  Monocytes (x10^9^/L)                                     NS               NS         NS
  CRP (mg/dL)                     142          0.24        \<0.01           NS         NS
  Erythrocyte count (x10^12^/L)   182          −0.33       \<0.0001         NS         NS
  Hemoglobin (g/dL)               186          −0.31       \<0.0001         NS         NS
  Hematocrit (L/L)                188          −0.27       \<0.001          NS         NS

CRP (C-reactive protein).

[^1]: Both authors contributed equally.
